Many Biobanks are under pressure to adopt more sustainable, business-like mentalities in the future. The results of a ISBER survey on business planning in the Biobanking community is outlined in this post.
A recent study has found that only around 9% of biobanks have a publicly available access policy. Given that most biobanks are funded by the public, there is an expectation that the samples they contain are made available for external research purposes that could ultimately have a social benefit. But for this to happen, clear access policies need to govern the conditions under which samples can be used for external… Read More »Only a minority of biobanks have a publicly available access policy
Spotlight on: Gautam Mehta Job title: Honorary Consultant and Senior Lecturer, UCL Research Project: Gautam is exploring new ways to treat patients with liver failure and alcohol-related liver disease. Liver disease is the third commonest cause of preventable death in the UK and rates are rising rapidly, therefore new treatments are urgently needed. Gautam’s research involves sequencing RNA (part of the genetic code of cells) from human liver and immune cells… Read More »Spotlight on: Gautam Mehta
Spotlight on: Ana Rio-Machin Job title: Postdoctoral Researcher at Barts Cancer Institute (BCI), Queen Mary University of London Research Project: Ana researches the genetic alterations (mutations) that are inherited in families who have leukaemia without a known cause, within a Bloodwise funded programme; ‘Acute Myeloid Leukaemia (AML) familial cases, where two or more affected individuals are found in the same family, are rare but represent a high-risk group of patients… Read More »Spotlight on: Ana Rio-Machin